New OSM CAR-T Therapy Shows Promise Against Childhood Bone Cancer
A new approach to treating osteosarcoma, the most common type of bone cancer affecting children and young adults, is showing promise in early research. For decades, treatment for this aggressive cancer has largely relied on a combination of chemotherapy and surgery, with limited advancements. Now, a study published in BMC Medicine details the successful use of a specially engineered immune-cell therapy, called OSM CAR-T, in mouse models.
Understanding Osteosarcoma and Its Challenges
Osteosarcoma primarily affects children, teenagers, and young adults during periods of rapid bone growth. Approximately 1,000 new cases are diagnosed annually in the United States, according to The Osteosarcoma Institute. Although the exact cause remains unknown, it’s believed to be linked to DNA changes within bone-forming cells, and, less frequently, genetic predisposition, as noted by the American Cancer Society. The difficulty in treating osteosarcoma stems from its tendency to metastasize – to spread to other parts of the body – and the limitations of current therapies in effectively targeting these spread cells.
“For the past 40 years, conventional therapies for osteosarcoma…have not changed much,” explains Reshmi Parameswaran, associate professor at Case Western Reserve School of Medicine and lead researcher of the study. “Our new approach offers the possibility of a targeted treatment that harnesses the body’s own immune system to fight the cancer—potentially offering better outcomes with fewer side effects than traditional chemotherapy.”
CAR-T Therapy: A Revolution with Limitations
The foundation of this new therapy lies in CAR-T (Chimeric Antigen Receptor T-cell) therapy, a groundbreaking treatment that reprograms a patient’s own immune cells to recognize and destroy cancer cells. CAR-T therapy has dramatically improved outcomes for blood cancers like leukemia and lymphoma. However, its effectiveness against solid tumors, such as osteosarcoma, has been limited. The National Cancer Institute (NCI) points out that solid tumor cancer cells are more complex, displaying varied markers on their surfaces, making it difficult for CAR-T cells to consistently identify and attack all cancerous cells.
Targeting Oncostatin M for Enhanced Effectiveness
The research team at Case Western Reserve University and University Hospitals overcame this challenge by engineering a CAR-T cell specifically designed to target receptors of Oncostatin M (OSM), a protein found on the surface of osteosarcoma cells. This represents a novel strategy, enabling the engineered immune cells to simultaneously recognize multiple receptors on cancer cells. Recent research has explored using AI to design these bi-specific CAR-T cells, further refining their targeting capabilities.
“The OSM CAR-T cell therapy showed anti-tumor effects against all osteosarcoma patient samples tested,” Parameswaran stated. Critically, the therapy also demonstrated effectiveness in eliminating tumor cells that had spread to other organs in mouse models – a significant finding, as metastatic disease is a major obstacle to successful treatment. This suggests the potential to address a critical unmet necessitate for patients with advanced osteosarcoma.
The Collaborative Research Behind the Breakthrough
This discovery was facilitated by the collaborative research environment at Case Western Reserve University and the resources provided by its Comprehensive Cancer Center and University Hospitals. These institutions offer the necessary infrastructure, expertise, and resources to advance innovative cancer immunotherapies.
What’s Next: Clinical Trials and Potential Impact
The research team is preparing to initiate clinical trials within the next two years to evaluate the safety and efficacy of OSM CAR-T therapy in humans. If these trials are successful, this therapy could become a new treatment option for osteosarcoma, potentially reducing the need for extensive surgery and offering hope to patients with metastatic disease. The process of moving from successful animal studies to human trials involves rigorous review by regulatory bodies, such as the Food and Drug Administration (FDA), to ensure patient safety and scientific validity.
Further research will focus on optimizing the CAR-T cell design, identifying biomarkers to predict treatment response, and exploring combination therapies to enhance effectiveness. The team will also investigate potential strategies to mitigate any side effects associated with CAR-T therapy, such as cytokine release syndrome, a common but potentially serious complication.
This development offers a significant step forward in the fight against osteosarcoma, a cancer that has remained stubbornly difficult to treat for far too long. The promise of harnessing the body’s own immune system to combat this disease provides a beacon of hope for patients and families affected by this challenging condition.
Publication details
Daniel Feinberg et al, Oncostatin-M ligand-based CAR-T therapy displays robust anti-tumor activity against osteosarcoma, BMC Medicine (2026). DOI: 10.1186/s12916-026-04729-8
Journal information: BMC Medicine